Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 6, 2015, Pages 802-810

  Visca, Alfredo ^a   Bishop, Clark T ^b   Hilton, Sterling ^c   Hudson, Valerie M ^d  

^a Federazione Italiana Medici Pediatri   (Italy)

^b INTERMOUNTAIN HEALTHCARE   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Body mass index; Cachexia; Calprotectin; Cystic fibrosis; Glutathione; Nutritional status

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CALGRANULIN; CITRATE CALCIUM; GLUTATHIONE; OLIGOPEPTIDE;

ABDOMINAL PAIN; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIUM CULTURE; BLOATING; BLOOD SAMPLING; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; ERUCTATION; FECES LEVEL; FEMALE; FLATULENCE; GROWTH DISORDER; HEARTBURN; HUMAN; INFLAMMATION; MAINTENANCE THERAPY; MALE; NAUSEA; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING; WEIGHT GAIN; BODY HEIGHT; BODY WEIGHT; DRUG EFFECTS; INFANT; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; GLUTATHIONE; HUMANS; INFANT; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; OLIGOPEPTIDES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84946474081     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000738     Document Type: Article

References (33)

1. Smyth RL, Croft NM, O'Hea U, et al. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2000; 82:394-9.
2. Peterson ML, Jacobs DR Jr, Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics 2003; 112 (3 Pt 1):588-92.
3. Zemel BS, Jawad AF, FitzSimmons S, et al Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 2000; 137:374-80.
4. Thomson MA, Quirk P, Swanson C.E., et al. Nutritional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction. Nutrition 1995; 11:350-4.
5. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002; 57:596-601.
6. Konstan MW, Butler SM, Wohl M.E., et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142:624-30.
7. Smyth RL, Walters S. Oral calorie supplement for cystic fibrosis. Cochrane Database Syst Rev 2012; 10:CD000406.
8. Conway SP, Morton A, Wolfe S. Enteral tube feeding for cystic fibrosis. Cochrane Database Syst Rev 2008; 2:CD001198.
9. Stallings VA, Stark LJ, Robinson K.A., et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108:832-9.
10. Linsdell P, Hanrahan JW Glutathione permeability of CFTR. Am J Physiol 1988; 44:C323-6.
11. Gao L, Kim KJ, Yankaskas J.R., et al. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol Lung Cell Mol Physiol 1999; 277:L113-8.
12. Velsor LW, van Heeckeren A, Day BJ. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 2001; 281:L31-8.
13. Day BJ, van Heeckeren AM, Min E, et al. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 2004; 72: 2045-51.
14. Kogan I, Ramjeesingh M, Kidd J., et al. Characterization of glutathione permeability through the CFTR channel pore. Ped Pulmonol 2002; 24:189-90.
15. Kogan I, Ramjessingh M, Li C., et al. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 2003; 22:1981-9.
16. Peterson JD, Herzenberg LA, Vasquez K, et al Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A 1998; 95:3071-6.
17. Cho S, Urata Y, Iida T., et al. Glutathione downregulates the phosphorylation of I kappa B: autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells. Biochem Biophys Res Commun 1998; 253:104-8.
18. Gosset P, Wallaert B, Tonnel A.B., et al. Thiol regulation of the production of TNF-alpha, IL-6 and IL-8 by human alveolar macrophages. Eur Respir J 1999; 14:98-105.
19. Bengmark S, Jeppsson B. Gastrointestinal surface protection and mucosa reconditioning. JPEN J Parenter Enteral Nutr 1995; 19:410-5.
20. Ziegler TR, Evans ME, Fernandez-Estivariz C, et al. Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu Rev Nutr 2003; 23:229-61.
21. Hoensch H, Morgenstern I, Petereit G., et al. Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut 2002; 50:235-40.
22. Food and Drug Administration. List of active orphan products designation, entry for cachexon. www.fda.gov/downloads/ForIndustry/⋯/UCM162066.xls. Published May 5, 2009. Accessed November 7, 2012.
23. Henderson P, Casey A, Lawrence S.J., et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012; 107:941-9.
24. Aomatsu T, Yoden A, Matsumoto K., et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011; 56:2372-7.
25. Visca A, Bishop CT, Hilton S.C., et al. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J Cyst Fibros 2008; 7:433-6.
26. Bishop C, Hudson VM, Hilton S.C., et al. A pilot study of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005; 127:308-17.
27. Griese M, Kappler M, Eismann C., et al. Inhalation treatment with glutathione in patients with cystic fibrosis: a randomized clinical trial. Am J Respir Crit Care Med 2013; 188:83-9.
28. Tam J, Nash EF, Ratjen F, et al Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013; 7:CD007168.
29. Hudson VM. Rethinking cystic fibrosis pathology: the crucial role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Redox Biol 2001; 30:1440-61.
30. Jones DP, Coates RJ, Flagg E.W., et al. Glutathione in foods listed in National Cancer Institute's health habits and history food frequency questionnaire. Nutr Cancer 1992; 17:57-75.
31. Dalhoff D, Ranek L, Mantoni M., et al. Glutathione treatment of hepatocellular carcinoma. Liver 1992; 12:341-3.
32. Tedeschi M, De Cesare A, Oriana S, et al The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. Can Treat Rev 1991; 18:253-9.
33. Furukawa T, Meydani SN, Blumberg JB The potential benefits of dietary glutathione on immune function and other practical applications. In: Vina J, ed. Glutathione: Metabolism and Physiological Functions. New York: CRC Press; 1990. 355 pp.